Drugs / abobotulinumtoxinA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04936542 | Jun 2021 → Aug 2025 | — | Ipsen | Completed | No outcome recorded |
Press releases naming this drug 4 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | abobotulinumtoxinA | “Lack of head-to-head comparative safety and efficacy data for abobotulinumtoxinA (aboBoNT-A) and onabotulinumtoxinA (onaBoNT-A) represented an important gap for informed...” PMID 42159955 ↗ May 2026 |
| Known as | AboBoNT-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04936542 ↗ |
| Action | Inhibit | “Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor” CHEMBL2108570 ↗ |
| Modality | Protein / enzyme biologic | “Biological: AboBoNT-A” NCT04936542 ↗ |
| Route | Intramuscular | “To maintain blinding, a fixed volume (3.6 ml) will be injected into the target upper limb muscles (four wrist and finger flexors and biceps brachii).” PMID 34562231 ↗ Sep 2021 |
| Target | SNAP25 | “Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor” CHEMBL2108570 ↗ |